Stepping forward:T-cell redirecting bispecific antibodies in cancer therapy  

作　　者：Xiaojing Qin Wenjing Ning Han Liu Xue Liu Wenxin Luo Ningshao Xia 

机构地区：[1]State Key Laboratory of Vaccines for Infectious Diseases,Xiang An Biomedicine Laboratory,School of Public Health,Xiamen University,Xiamen 361102,China [2]National Institute of Diagnostics and Vaccine Development in Infectious Diseases,State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics,National Innovation Platform for IndustryeEducation Integration in Vaccine Research,the Research Unit of Frontier Technology of Structural Vaccinology of Chinese Academy of Medical Sciences,Xiamen University,Xiamen 361102,China

出　　处：《Acta Pharmaceutica Sinica B》2024年第6期2361-2377,共17页药学学报（英文版）

基　　金：supported by the National Natural Science Foundation of China(Nos.32070940 and 81991491);the China Postdoctoral Science Foundation(No.2021M700115);the Postdoctoral Innovation Talents Support Program(No.BX20220189,China);the Science and Technology Planning Project of Fujian Province(No.2022L3080,China);the CAMS Innovation Fund for Medical Sciences(No.2019RU022,China).

摘　　要：T cell-redirecting bispecific antibodies are specifically designed to bind to tumor-associated antigens,thereby engaging with CD3 on the T cell receptor.This linkage between tumor cells and T cells actively triggers T cell activation and initiates targeted killing of the identified tumor cells.These antibodies have emerged as one of the most promising avenues within tumor immunotherapy.However,despite success in treating hematological malignancies,significant advancements in solid tumors have yet to be explored.In this review,we aim to address the critical challenges associated with T cellredirecting bispecific antibodies and explore novel strategies to overcome these obstacles,with the ultimate goal of expanding the application of this therapy to include solid tumors.

关 键 词：Bispecific antibody(BsAbs) T-cell redirecting BsAbs Tumor-associated antigens TOXICITY Cytokine release syndrome Tumor microenvironment Cancer immunotherapy Combination therapy strategies 

分 类 号：R73-36[医药卫生—肿瘤]